Creatine in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Imagem de Miniatura
Arquivos
art_GUALANO_Creatine_in_Type_2_Diabetes_A_Randomized_DoubleBlind_2011.PDF (306.16 KB)
Citações na Scopus
73
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
PAINNELI, Vitor De Salles
ROSCHEL, Hamilton
ARTIOLI, Guilherme Giannini
CUNHA, Maria Rosaria
Citação
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, v.43, n.5, p.770-778, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
GUALANO, B., V. DE. SALLES PAINNELI, H. ROSCHEL, G. G. ARTIOLI, M. NEVES JR, A. L. DE SA PINTO, M. E. DA SILVA, M. R. CUNHA, M. C. G. OTADUY, C. DA COSTA LEITE, J. C. FERREIRA, R. M. PEREIRA, P. C. BRUM, E. BONFA, and A. H. LANCHA JR. Creatine in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Med. Sci. Sports Exerc., Vol. 43, No. 5, pp. 770-778, 2011. Creatine supplementation improves glucose tolerance in healthy subjects. Purposes: The aim was to investigate whether creatine supplementation has a beneficial effect on glycemic control of type 2 diabetic patients undergoing exercise training. Methods: A 12-wk randomized, double-blind, placebo-controlled trial was performed. The patients were allocated to receive either creatine (CR) (5 g.d(-1)) or placebo (PL) and were enrolled in an exercise training program. The primary outcome was glycosylated hemoglobin (Hb(A1c)). Secondary outcomes included the area under the curve of glucose, insulin, and C-peptide and insulin sensitivity indexes. Physical capacity, lipid profile, and GLUT-4 protein expression and translocation were also assessed. Results: Twenty-five subjects were analyzed (CR: n = 13; PL: n = 12). Hb(A1c) was significantly reduced in the creatine group when compared with the placebo group (CR: PRE = 7.4 +/- 0.7, POST = 6.4 +/- 0.4; PL: PRE = 7.5 +/- 0.6, POST = 7.6 +/- 0.7; P = 0.004; difference = -1.1%, 95% confidence interval = -1.9% to -0.4%). The delta area under the curve of glucose concentration was significantly lower in the CR group than in the PL group (CR = -7790 +/- 4600, PL = 2008 +/- 7614; P = 0.05). The CR group also presented decreased glycemia at times 0, 30, and 60 min during a meal tolerance test and increased GLUT-4 translocation. Insulin and C-peptide concentrations, surrogates of insulin sensitivity, physical capacity, lipid profile, and adverse effects were comparable between the groups. Conclusions: Creatine supplementation combined with an exercise program improves glycemic control in type 2 diabetic patients. The underlying mechanism seems to be related to an increase in GLUT-4 recruitment to the sarcolemma.
Palavras-chave
CREATINE SUPPLEMENTATION, EXERCISE TRAINING, TYPE 2 DIABETES, THERAPEUTIC EFFECTS
URI
https://observatorio.fm.usp.br/handle/OPI/22894
Referências
  1. ALSEVER R N, 1970, Endocrinology, V86, P332
  2. Ferrante RJ, 2000, J NEUROSCI, V20, P4389
  3. Wyss M, 2000, PHYSIOL REV, V80, P1107
  4. Green AL, 1996, AM J PHYSIOL-ENDOC M, V271, pE821
  5. Ju JS, 2005, AM J PHYSIOL-ENDOC M, V288, pE347, DOI 10.1152/ajpendo.00238.2004
  6. Robinson TM, 2000, BRIT J SPORT MED, V34, P284, DOI 10.1136/bjsm.34.4.284
  7. Rooney K, 2002, METABOLISM, V51, P518, DOI 10.1053/meta.2002.31330
  8. NEWCOMER KL, 1993, J RHEUMATOL, V20, P21
  9. Branch JD, 2003, INT J SPORT NUTR EXE, V13, P198
  10. Gualano B, 2008, AMINO ACIDS, V34, P245, DOI 10.1007/s00726-007-0508-1
  11. Deldicque L, 2005, MED SCI SPORT EXER, V37, P731, DOI 10.1249/01.MSS.0000162690.39830.27
  12. Poortmans JR, 2000, SPORTS MED, V30, P155, DOI 10.2165/00007256-200030030-00002
  13. Sigal RJ, 2004, DIABETES CARE, V27, P2518, DOI 10.2337/diacare.27.10.2518
  14. Safdar A, 2008, PHYSIOL GENOMICS, V32, P219, DOI 10.1152/physiolgenomics.00157.2007
  15. Henriksen EJ, 2002, J APPL PHYSIOL, V93, P788, DOI 10.1152/japplphysiol.01219.2001
  16. Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035
  17. MARCO J, 1976, FEBS LETT, V64, P52, DOI 10.1016/0014-5793(76)80246-3
  18. Ryder JW, 2000, DIABETES, V49, P647, DOI 10.2337/diabetes.49.4.647
  19. Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504
  20. GUALANO B, AMINO ACIDS, V38, P31
  21. Johansen K, 1999, DIABETES CARE, V22, P33, DOI 10.2337/diacare.22.1.33
  22. Newman JEN, 2003, MED SCI SPORT EXER, V35, P69, DOI [10.1249/01.MSS.0000043288.85309.2E, 10.1097/00005768-200301000-00012]
  23. Op 't Eijnde B, 2001, Diabetes, V50, P18
  24. Op't Eijnde B, 2006, INT J MOL MED, V17, P1077
  25. Paddon-Jones D, 2004, J NUTR, V134, p2888S
  26. Persky Adam M., 2007, V46, P275
  27. Thomas DE, 2006, COCHRANE DB SYST REV, V3
  28. van Loon LJC, 2004, CLIN SCI, V106, P99, DOI 10.1042/CS20030116

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/18
Carregar mais